All Trials

Phase 1 Trial of Nab-Paclitaxel PIPAC (Pressurized Intraperitoneal Aerosolized Chemotherapy) Given in Combination With Second-Line Therapy for Gastric Cancer With Peritoneal Metastases

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with gastric adenocarcinoma and visible peritoneal metastases after failure of first-line fluoropyrimidine/platinum (ECOG 0–1) receive intraperitoneal nab‑paclitaxel via PIPAC added to standard second-line paclitaxel plus ramucirumab. Nab‑paclitaxel (albumin-bound paclitaxel enhancing intratumoral delivery) is dosed by PIPAC every 56 days for up to 3 cycles alongside fixed-dose systemic paclitaxel/ramucirumab to determine safety and dosing, with limited prior second-line therapy allowed.

ClinicalTrials.gov ID: NCT06675136

A Phase IIa Study of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) and PD-L1 Expression in Gastric Cancer With Peritoneal Metastases

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with gastric cancer limited to peritoneal metastases or positive cytology after 2–4 months of prior chemotherapy receive repeated interval laparoscopic HIPEC with cisplatin and mitomycin C to assess PD-L1 upregulation in peritoneal tumors. Secondary aims include conversion to resectability, PCI reduction, survival, and perioperative safety, with interest in outcomes among PD-L1–positive patients who may receive systemic PD-1 inhibitors.

ClinicalTrials.gov ID: NCT04107077

A Pilot Study of Pembrolizumab and Lenvatinib Combination Therapy in Patients With Previously Treated Advanced Gastroesophageal Adenocarcinoma

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Single-arm study for adults with unresectable or metastatic gastric/GEJ adenocarcinoma after failure of prior systemic therapy, requiring measurable disease and ECOG 0–1, excluding prior PD-1/PD-L1 or VEGF/lenvatinib exposure. Patients receive pembrolizumab (anti–PD-1) plus lenvatinib (oral multikinase inhibitor of VEGFR/FGFR/PDGFR/KIT/RET) to assess response, with secondary endpoints including durability, PFS/OS, and safety.

ClinicalTrials.gov ID: NCT05041153

A Phase II Study of Robotic Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Patients With Gastric Cancer and Limited Peritoneal Metastasis: ROBO-CHIP Trial

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with gastric or Siewert II/III GEJ adenocarcinoma with peritoneal-only metastases and low tumor burden (PCI ≤7) after response to systemic therapy undergo robotic cytoreductive gastrectomy followed by HIPEC with cisplatin (DNA crosslinking platinum) and docetaxel (microtubule-stabilizing taxane). Trial focuses on perioperative safety and recovery metrics in this minimally invasive approach compared with historical open standards.

ClinicalTrials.gov ID: NCT05753306

A Phase II Study of Perioperative Paclitaxel in Patients With Gastric Adenocarcinoma and Carcinomatosis or Positive Cytology

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with stage IV gastric or GEJ adenocarcinoma limited to peritoneal disease (positive cytology and/or carcinomatosis) after preoperative systemic chemotherapy receive intraperitoneal paclitaxel every 2 weeks perioperatively, with gastrectomy considered at investigator discretion. Paclitaxel is a microtubule-stabilizing cytotoxic agent; HER2 therapy and PD-1 inhibitors may continue, and the trial emphasizes safety and feasibility of IP delivery and surgery in this setting.

ClinicalTrials.gov ID: NCT05977998

Ramucirumab Plus Trifluridine/Tipiracil (TAS-102) for Patients With Previously Treated Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: An Investigator-Initiated, Randomized Non-Inferiority Phase 2 Study

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with unresectable or metastatic gastric/GEJ adenocarcinoma progressing after fluoropyrimidine/platinum (and trastuzumab if HER2+) are randomized to ramucirumab (VEGFR-2 antibody) plus oral trifluridine/tipiracil (TAS-102, nucleoside analog with thymidine phosphorylase inhibitor) versus the standard ramucirumab plus paclitaxel as second-line therapy. Key eligibility: ECOG 0–1, adequate organ function, no prior ramucirumab/TAS-102 or recent taxane exposure, and ability to take oral therapy.

ClinicalTrials.gov ID: NCT04660760

COordinated Nivolumab and IntraperiToneal IL-2 for Gastric CanceR with PeritOneaL Metastasis (CONTROL) Phase 1b Pilot Study

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with gastric or GEJ adenocarcinoma limited to peritoneal metastases (PCI 1–24), ECOG 0–2, starting or on first-line FOLFOX plus nivolumab without progression. Adds intraperitoneal aldesleukin (IL-2; immune-stimulatory cytokine activating T cells/NK cells) on days 1 and 8 of each 14‑day cycle with standard FOLFOX+nivolumab to reduce peritoneal disease; excludes non-peritoneal mets and prior checkpoint/IL-2.

ClinicalTrials.gov ID: NCT05802056

A Phase II Study Of Neratinib In Combination With Chemotherapy/Trastuzumab/Pembrolizumab In HER2 Overexpressing Gastroesophageal Cancers

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with previously untreated, HER2-overexpressing/metastatic esophageal, gastric, or GEJ adenocarcinoma (IHC 3+ or FISH+ if IHC 2+), ECOG 0–1, receive neratinib (irreversible pan-HER TKI targeting EGFR/HER2/HER4) added to mFOLFOX plus trastuzumab and pembrolizumab; treated/stable brain metastases allowed. Excludes active CNS disease, significant cardiac disease, >grade 1 neuropathy, active autoimmune disease on systemic therapy, pneumonitis, active infection, or chronic steroids >10 mg prednisone equivalent.

ClinicalTrials.gov ID: NCT06109467

Randomized Phase II Rescuing Cancer Immunotherapy With Plasma Exchange in Bladder Cancer 1 (ReCIPE-B1)

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with metastatic urothelial carcinoma that progressed after prior enfortumab vedotin plus pembrolizumab are randomized to re-challenge with enfortumab vedotin (nectin-4–targeting ADC delivering MMAE) plus pembrolizumab (PD-1 inhibitor) with added therapeutic plasma exchange (days 1–3 of cycles 1–3) versus physician’s choice next-line standard of care. Eligible patients have measurable disease and ECOG 0–2; key exclusions include variant histologies (neuroendocrine, micropapillary, signet ring) and significant comorbidity.

ClinicalTrials.gov ID: NCT07087860

Phase II Study of Olaparib in Metastatic Renal Cell Carcinoma Patients Harboring a BAP-1 or Other DNA Repair Gene Mutations (ORCHID)

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Single-arm study of olaparib, an oral PARP1/2 inhibitor, in adults with metastatic RCC (clear or non–clear cell) harboring pathogenic BAP1 or other DDR/HRR gene alterations (e.g., ATM, BRCA1/2, PALB2), after prior ICI and/or anti-VEGF therapy. Eligible patients require ECOG 0–1 and measurable disease; prior PARP inhibitor use and uncontrolled CNS disease are excluded.

ClinicalTrials.gov ID: NCT03786796